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fronto-temporal (Lawrie et al., 2002), frontal–parietal (Schlösser 
et al., 2003a, 2005), frontal–cerebellar, cerebellar–thalamic, and 
thalamo-cortical (Schlösser et al., 2003b) connectivity in patients 
with schizophrenia. In addition, studies using the diffusion tensor 
imaging (DTI) technique have shown reduced fractional anisotropy 
(FA) – evidence of impaired white matter integrity, in several brain 
regions, including prefrontal, temporal, parietal, and occipital lobes 
(Heimer, 2000; Middleton and Strick, 2000; Kanaan et al., 2005; 
Kubicki et al., 2007), as well as some of the fiber bundles connect-
ing these regions, such as uncinate fasciculus (Andreasen et al., 
1997), cingulum bundle (Benes, 2000; Grace, 2000; Carlsson et al., 
2001), and arcuate fasciculus (Andreasen et al., 1997). Such changes 
have also been seen in the brains of never-medicated, first-episode 
schizophrenia patients (Chua et al., 2007), and in neuroleptic-naïve 
schizophrenics (Zou et al., 2008). Interestingly, patients with white 
matter lesions, such as leukodystrophies, leukoencephalopathies, 
and multiple sclerosis, often present with psychotic symptoms 
that are sometimes indistinguishable from those of schizophrenia 
(Davis et al., 2003; Walterfang et al., 2005; Denier et al., 2007). 
Taken together, the existing evidence from human studies suggests a 
primary role for compromised white matter in the  pathophysiology 
of schizophrenia.
IntroductIon
Schizophrenia is a severe and chronic mental illness affecting 
0.5–1% of the worldwide population. Patients with schizophre-
nia show abnormal mental functions that have been categorized 
into positive (hallucinations, delusions, and thought or speech 
disorganization) and negative symptoms (affect flattening, apathy, 
and social withdrawal). In addition, disturbances in basic cogni-
tive functions, such as attention, executive function, and specific 
forms of memory (particularly working memory), are also con-
sistently observed in sufferers of this disorder (Andreasen et al., 
1994; Andreasen, 1995). Some patients even show concomitant 
mood symptoms including depression and anxiety (Carpenter 
and Buchanan, 1994). These diverse symptoms and disturbances 
have not been attributable to abnormalities in any single brain 
area or neurotransmitter system.
One explanation proposed to account for this broad array of 
schizophrenia symptoms is a reduction in connectivity between 
brain regions (Selemon and Goldman-Rakic, 1999; Hoffman and 
McGlashan, 2001), particularly affecting the prefrontal cortex 
(PFC) and its connections with the limbic system, the striatum, 
and the thalamus. In support of this theory, functional magnetic 
resonance imaging (fMRI) studies have documented altered 
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In spite of the aforementioned work, there are few studies that 
correlate the disease progression with changes in white matter and 
examine effects of existing effective antipsychotic drugs on com-
promised white matter. To accomplish these goals, animal studies 
are indispensable. In recent studies (Xiao et al., 2008; Makinodan 
et al., 2009; Xu et al., 2009), C57BL/6 mice with demyelination and 
oligodendrocyte loss caused by cuprizone (CPZ) showed a number 
of abnormal behaviors, including deficits in prepulse inhibition 
(PPI), reduced social interaction (SI), and impaired spatial working 
memory. CPZ is a copper chelator with neurotoxic effects for mouse 
and rat. Studies have demonstrated that mice, after consuming 
CPZ-containing diet for several weeks, show widespread demyeli-
nation, myelin breakdown, and oligodendrocyte loss (Matsushima 
and Morell, 2001; Remington et al., 2007). However, other cell 
types in the central nervous system were not affected (Selvaraju 
et al., 2004). In another study, CPZ-treated rats displayed a specific 
deficit in the ability to shift between perceptual dimensions in the 
attention set-shifting task, a PFC-mediated behavioral paradigm 
(Gregg et al., 2009) which parallels to the Wisconsin card sorting 
test. Therefore, the CPZ-fed rodents appear to be a useful animal 
model for exploring the role of white matter abnormalities in the 
pathophysiology of schizophrenia (Herring and Konradi, 2011).
With the above-mentioned long-term goal in mind, in a recent 
animal study we examined effects of the antipsychotic drugs halo-
peridol (HAL), clozapine (CLZ), and quetiapine (QUE) on the 
CPZ-induced behavioral changes and white matter damage in 
C57BL/6 mice (Xu et al., 2010). Administration of HAL (1 mg/kg/
day, i.p.) significantly ameliorated the PPI deficit and spatial work-
ing memory impairment in mice consuming a CPZ-containing diet; 
HAL showed no effect on the CPZ-induced deficit in SI of mice. 
CLZ (10 mg/kg/day, i.p.) and QUE (10 mg/kg/day, i.p.) not only 
prevented mice from all the above mentioned CPZ-induced behav-
ioral changes, but also protected against the CPZ-induced white 
matter damage (Xu et al., 2010). These different effects of HAL, 
CLZ, and QUE on CPZ-induced behavioral changes and white 
matter damage in mice encouraged us to perform the current study.
In the present study, young adult male C57BL/6 mice were fed 
the CPZ-containing diet for 5 weeks then returned to normal food 
without CPZ for 3 weeks as the recovery period, during which 
the antipsychotic drugs HAL, CLZ, olanzapine (OLZ), or QUE 
were administered. HAL is a prototype of the first-generation 
or typical antipsychotic drugs. The therapeutic effects of typical 
antipsychotic drugs are predominantly limited to positive symp-
toms of schizophrenia (Kane et al., 1998; Weiss et al., 2002). This 
action is most likely due to their ability to block dopamine D
2
 
receptors in mesolimbic areas (Davis et al., 1991). These drugs are 
also associated with a variety of extrapyramidal side-effects (EPS; 
Gerlach, 2002), which, in turn, may exacerbate negative symptoms 
and cognitive impairment of patients with schizophrenia (Jibson 
and Tandon, 1998). CLZ, OLZ, and QUE are second-generation or 
atypical antipsychotic drugs. In addition to their efficacy on positive 
symptoms, atypical antipsychotic drugs have been reported to ame-
liorate negative symptoms of schizophrenia compared to placebo 
(King, 1998; Muller, 1999). Furthermore, these drugs have some 
beneficial effects on cognitive function of schizophrenic patients 
(Weiss et al., 2002; Woodward et al., 2005). Atypical antipsychotic 
drugs affect the dopaminergic system to a lesser extent than typical 
antipsychotic drugs and, in addition, inhibit serotonergic, mus-
carinic, histaminergic, and α1 adrenergic receptors (see the review 
by Konradi and Heckers, 2001).
The goals of this study were to see the recovery processes of 
CPZ-induced behavioral changes and damaged white matter and to 
examine possible effects of these antipsychotic drugs on the recov-
ery processes. The behavioral tests applied in this study include 
elevated plus-maze (EPM), SI, and Y-maze tests. EPM test is used 
to measure anxiety levels of mice, which has relevance to the anxi-
ety symptoms of schizophrenic patients; low levels of SI in mice 
is the analogous behavior of social withdrawal of patients with 
schizophrenia; Y-maze test is used to measure the short-term spatial 
memory of rodents, which is relevant to schizophrenia as patients of 
this disease have cognitive impairment including memory deficits. 
Spontaneous recovery was expected since significant remyelination 
occurs following withdrawal of CPZ (Stidworthy et al., 2003). Also, 
we expected that HAL might have different effects on the recovery 
of the CPZ-induced changes than the atypical antipsychotic drugs 
used in this study.
MaterIals and Methods
anIMals
All animal procedures in this study were in accordance with the 
National Institute of Health Guide for the Care and Use of Laboratory 
Animals and were approved by the Animal Care and Use Committee of 
Southern Illinois University at Carbondale. Young adult male C57BL/6 
mice (6 weeks old) were obtained from Charles River Laboratories 
(Wilmington, MA, USA) and housed in the vivarium of Southern 
Illinois University at Carbondale with a 12 h dark/12 h light cycle, at 
a constant temperature of 22 ± 1°C and a relative humidity of 60%. 
Young adult mice were chosen in this study as they have been dem-
onstrated to be more sensitive to CPZ treatment and have been com-
monly used in previous studies (Xiao et al., 2008; Zhang et al., 2008; 
Makinodan et al., 2009; Xu et al., 2009, 2010). Although male and 
female C57BL/6 mice showed the same demyelination after consuming 
CPZ-containing diet in previous study (Stidworthy et al., 2003), only 
male mice were used in this study to minimize behavioral variance.
experIMental protocols
Two experiments were performed in this study. In experiment 1 
(Figure 1), mice (n = 60) ate the rodent chow mixed with CPZ 
(Sigma-Aldrich, St. Louis, MO, USA) at 0.2% w/w for 5 weeks. 
During the last 3 days of the fifth week, the mice were evaluated in 
EPM, SI, and Y-maze tests in three groups of 20 each. Then, mice 
were fed the normal rodent chow without CPZ for 3 weeks to allow 
them to recover. During the recovery period, mice were subjected 
to the following post-CPZ treatments in groups of 12 each: vehicle 
(VEH) in which mice ate normal diet and received intraperitoneal 
(i.p.) injection of the vehicle (0.4% acetic acid in saline, 10 ml/kg) 
once a day for 21 days, CLZ in which mice ate normal diet and 
received CLZ i.p. once a day for 21 days (10 mg/kg; Sigma-Aldrich), 
HAL in which mice ate normal diet and received HAL (1 mg/kg; 
Sigma-Aldrich), OLZ in which mice ate normal diet and received 
OLZ (3 mg/kg; Lilly Research Laboratories, Indianapolis, IN, USA), 
QUE in which mice ate normal diet and received QUE (10 mg/kg; 
AstraZeneca, Wilmington, DE, USA). These dosages were chosen 
on the basis of previous studies (Chlan-Fourney et al., 2002; Bai 
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et al., 2004; Zhang et al., 2008). In the last 3 days of the second 
and third week of the recovery period, all mice were subjected to 
the same behavioral tests as those used in the end of CPZ-feeding 
phase. On day 22, all mice were sacrificed under deep anesthesia and 
their brains were processed for morphological analyses. Choosing 
5 weeks for the CPZ-feeding phase and 3 weeks for recovery was 
based on previous studies, which showed that after 5 or 6 weeks of 
continuous CPZ administration demyelination is maximal and that 
CPZ withdrawal at this stage results in significant remyelination 
over the course of about 4 weeks (Matsushima and Morell, 2001).
In the second experiment, mice (n = 60) were randomly divided 
into five groups of 12 each and subjected to the same treatments of 
VEH, CLZ, HAL, OLZ, and QUE for 21 days as in the recovery phase 
of the first experiment. During this period mice were fed a normal diet 
without CPZ. In the last 3 days of the third week mice were assessed in 
the same behavioral tests as in the first experiment. These groups were 
used to determine effects of the antipsychotic drugs on behaviors of 
normal mice. In addition, behaviors from normal mice (n = 12) that 
had never eaten the CPZ-containing diet nor received antipsychotic 
drugs in our previous study (Xu et al., 2009) were used as normal 
controls (CNT); five mice that ate CPZ-containing diet for 5 weeks in 
the same study were used as a comparator for morphological analyses.
BehavIoral tests
Elevated plus-maze, SI, and Y-maze tests were performed as 
described previously (Xu et al., 2009). They were performed before 
the injection of the vehicle or antipsychotic drugs on the same day. 
EPM was to measure anxiety levels of mice as they avoid the open 
arms of the plus-maze (Lister, 1990). Briefly, a mouse was initially 
placed in the center area facing an open arm. The mouse’s entry 
into any of the four arms was counted when all four paws crossed 
from the central region into an arm. The number of total arm 
entries and the amount of time spent on the open arms during a 
10-min testing period were recorded.
The SI test was to evaluate social withdrawal, a key component of 
the negative symptoms of patients with schizophrenia (Weinberger, 
1987; Abi-Dargham et al., 2000). Pairs of unfamiliar mice (housed 
in separate cages) of the same experimental group were initially 
placed in the center of an open-field box (56 cm × 56 cm × 31 cm) 
about 10 cm apart. A video camera was placed above the open-
field box to monitor the animals’ movements. During a 10-min 
test period, SI was defined as when the subjects were closer than 
5 cm (between the center points of the back of one mouse and 
the other one) for at least 0.2 s. Data were recorded and analyzed 
automatically using the SMART video tracking program (San Diego 
Instruments, San Diego, CA, USA). Although this method only 
measures subject proximity, it has been used in previous studies 
to evaluate SIs (Shi et al., 2003; Egashira et al., 2007).
Y-maze test is a simple recognition test for measuring spatial work-
ing memory (Maurice et al., 1994; Dellu et al., 2000). Each mouse was 
placed at the end of one arm of a Y-maze (two shorter arms of 15 cm 
and a longer arm of 20 cm) and allowed to move freely through the 
maze for an 8-min test period. Alternation was defined as successive 
entries into the three arms on overlapping triplet sets. The maximum 
number of possible spontaneous alternations was determined as the 
total number of arms entered – 2, and the percentage correct was 
calculated as the ratio of actual to possible alternations × 100.
MorphologIcal analyses
Mice were deeply anaesthetized with chloral hydrate (400 mg/kg, 
i.p.) and perfused through the ascending aorta with 0.1 M phos-
phate buffered saline (PBS, pH = 7.4), followed by 4% paraform-
aldehyde in PBS. Their brains were then removed and post-fixed 
overnight in the same fixative, followed by cryoprotection in 25% 
sucrose at 4°C for 24–48 h. Serial coronal sections (25 μm thick) 
were cut using a sliding microtome (Lipshaw, Detroit, MI, USA) 
and collected in six-well plates containing 0.01 M PBS.
One set of the sections was used to evaluate myelinated fibers using 
luxol fast blue–periodic acid Schiff (LFB–PAS) staining. The other two 
sets of sections were used for immunohistochemical staining. Briefly, 
free-floating sections were pre-treated with 0.5% hydrogen peroxide 
in methanol for 20 min, then washed with PBS and incubated for 1 h 
at 22°C in a blocking solution composed of 1% Triton X-100 and 5% 
normal (goat/rabbit) serum in PBS. The sections were subsequently 
incubated in the blocking solution for 48 h at 4°C with the primary 
antibody to MBP (1:6000; Chemicon, Temecula, CA, USA) or to GST-pi 
(the pi form of glutathione-transferase; 1:500; Stressgen, Victoria, BC, 
Canada). Anti-MBP detects myelin tracts while anti-GST-pi labels 
mature oligodendrocytes (Mason et al., 2004). After rinsing in PBS, 
brain sections were incubated in the biotinylated secondary antisera 
(1:200) of the Vectastain (Elite) ABC kit (Burlingame, CA, USA) for 
2 h at 22°C. Following PBS rinses, the sections were then incubated 
in an avidin–biotin–horseradish peroxidase complex (ABC) for 1 h at 
22°C. Finally, the antigen–antibody complexes were visualized using 
0.025% 3, 3′-diaminobenzidine (DAB, Sigma-Aldrich, St. Louis, MO, 
USA) as the chromogen. Immunohistochemical controls were done 
as above except that the primary antibodies were omitted.
The processed brain sections were examined using a Leica 
DMI 4000 B microscope (Leica Microsystems, Wetzlar, Germany). 
In immunohistochemically stained sections, no positive 
Figure 1 | The time-line and schedule for the behavioral tests in experiment. CPZ, cuprizone; EPM, elevated plus-maze; SI, social interaction.
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results
cpZ-Induced BehavIoral changes and whIte Matter daMage
Mice fed CPZ-containing diet for 5 weeks spent longer peri-
ods (total end count ≥ 10, p < 0.001) on open arms of EPM 
(Figure 2A), but less time (total end count ≥ 7, p < 0.05) in SI 
(Figure 3A), and showed lower spontaneous alternation (total 
end count ≥ 10, p < 0.001) in the Y-maze (Figure 4A), as com-
pared to the CNT group. However, the CPZ-induced increase 
in the number of arm entries in Y-maze test did not reach a 
significant level (data are not shown), suggesting the treatment 
did not affect the locomotor activity of mice. The CPZ-fed mice 
showed complete demyelination (Figure 5B), widespread myelin 
break-down (Figure 6B), and oligodendrocyte loss (Figure 7B) 
in their brains.
the cpZ-Induced aBnorMal BehavIor In epM spontaneously 
recovered to norMal By 14th day after cpZ wIthdrawal
The aforementioned disrupted behaviors showed different recov-
ery processes during the 3-week recovery period. On day 14 after 
CPZ withdrawal, the increased time spent on open arms of the 
EPM returned to the level of CNT group (see the dotted line in 
Figure 2A). The same normalized performance was also seen on 
 immunostaining was found in the control sections. The normal 
myelin sheaths (in experiment 1) appeared blue in LFB–PAS stain-
ing and in brown in MBP-immunohistochemistry. The area of blue 
myelin sheaths in the central part of corpus callosum (CC) and 
MBP-positive staining (in brown) in the medial dorsal cerebral 
cortex (CTX) were measured using the Image-Pro Plus software 
(version 4.1, Media Cybernetics, Inc., Silver Spring, MD, USA) and 
values of normal control group (CNT) were used as comparators 
for all other groups. That is, values of all other groups were nor-
malized as percentages of CNT group. The numbers of GST-pi 
positive cells in CTX of mice were counted (five sections/mouse) 
and expressed as number per square millimeter.
data analysIs
The behavioral data from the CNT group (in which mice ate rodent 
chow without CPZ) and that obtained at the end of CPZ-feeding 
phase were analyzed with the Tukey quick test. For the data obtained 
at the three time points of the recovery phase, two-way ANOVA 
was performed considering the recovery time and antipsychotics 
as two factors. The data of the second experiment were analyzed 
by one-way ANOVA followed by a post hoc (Scheffe’s) test. When a 
p-value was less than 0.05, the difference was considered significant.
Figure 2 | Complete recovery of abnormal elevated plus-maze behavior after CPZ withdrawal. (A) The data from the recovery experiment, in which the dotted 
line indicates the value of the controls (CNT) never exposed to CPZ or antipsychotic drugs. (B) The data from mice exposed to antipsychotics, but not to CPZ. Data 
are mean ± SEM (n = 6–12/group). VEH, vehicle; CLZ, clozapine; HAL, haloperidol; OLZ, olanzapine; QUE, quetiapine.
Figure 3 | Social interaction deficit did not recover after CPZ withdrawal. (A) The data from the recovery experiment, in which the dotted line indicates the 
value of the controls (CNT), which was significantly higher than all other groups. (B) The data from mice exposed to antipsychotics, but not to CPZ. Data are 
mean ± SEM (n = 6/group). *p < 0.05.
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groups showed comparable time on open arms of EPM. One-way 
ANOVA indicated no effect (F
4, 41
 = 0.73; p = NS) of the antipsy-
chotics on the time spent on open arms of the EPM.
the cpZ-Induced sI defIcIt reMaIned at low levels durIng the 
recovery phase and was not affected By antIpsychotIc 
treatMent
The decreased SI time measured on day 0 remained at low lev-
els during the 3-week recovery phase in all CPZ-withdrawn 
mice. Two-way ANOVA analysis indicated a significant effect of 
day 21 after CPZ withdrawal. Two-way ANOVA analysis indicated 
a significant effect of recovery time (F
2, 135
 = 66.80; p < 0.0001) 
but no significant effect of treatment (F
4, 135
 = 0.15; p = NS). Post 
hoc comparisons showed significant differences between the data 
obtained on day 14 after CPZ withdrawal and those on day 0 (the 
end of CPZ-feeding phase). Significant differences also existed 
between the data obtained on day 21 and those on day 0. When 
comparisons were made between data obtained on days 14 and 21, 
no significant differences were found between the VEH group and 
any antipsychotic group. In the second experiment (Figure 2B), all 
Figure 4 | Atypical antipsychotic drugs, but not haloperidol, promoted the recovery of spontaneous alternation after CPZ withdrawal. (A) The data from 
the recovery experiment, in which the dotted line indicates the value of the controls (CNT). (B) The data from mice exposed to antipsychotics, but not to CPZ. Data 
are mean ± SEM (n = 6–12/group). **p < 0.01, compared to CNT.
Figure 5 | incomplete remyelination of the corpus callosum (CC) after CPZ 
withdrawal. (A) An image from an animal of the control (CNT) group showing 
normal myelinated fibers (in blue) in CC. (B) An image from a mouse exposed to CPZ 
for 5 weeks showing no normal myelinated fibers in CC. (C) An image from a mouse 
treated with VEH during the 3-week recovery period after CPZ withdrawal. (D) The 
quantitative data (mean ± SEM; n = 5/group). The dotted line indicates the value of 
the CNT group, which was significantly higher than all other groups. **p < 0.01, 
compared to the CPZ group. The scale bar in the image (C) represents about 250 μm.
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the recovery of coMproMIsed whIte Matter was not coMplete 
In the 3-week recovery phase
Normal myelinated neural fibers were stained blue in LFB–PAS-
stained brain sections, exemplified by a microphotograph of the 
CC (Figure 5A). Blue staining was rarely seen in the CC of mice 
exposed to CPZ for 5 weeks (Figure 5B), suggesting widespread 
demyelination. After recovery for 3 weeks blue staining in the CC 
reappeared and occupied the most part of CC, although a few resid-
ual demyelinated fibers (in red) were still visible (Figure 5C). This 
pattern was observed in the CC of all CPZ-withdrawn mice (images 
from antipsychotic-treated mice are not shown). The differences 
between the CNT group and the VEH- or antipsychotics-treated 
groups were significant (Figure 5D).
Fine MBP-positive fibers were well illustrated in brain sections 
from CNT mice (Figure 6A). In contrast, the mice exposed to CPZ 
for 5 weeks showed widespread myelin break-down, which was 
most obvious in CTX (Figure 6B). After 3 weeks recovery following 
CPZ withdrawal, the MBP immunostaining in the CTX seemed 
to be similar to that of normal mice under a lower magnification 
(Figure 6C). One-way ANOVA performed for the quantitative 
data of groups VEH, CLZ, HAL, OLA, and QUE in experiment 
1 showed no significant effect (F
4, 24
 = 1.43; p = NS) of treatment 
on the MBP immunostaining in CTX. And post hoc comparisons 
showed no differences between VEH and any antipsychotic group 
as well as between any two antipsychotic groups. However, when 
comparisons (Student’s t-test) were made between the CPZ group 
and anyone of the above-mentioned groups, differences were sig-
nificant. The differences between the CNT group and the VEH- or 
antipsychotics-treated groups were not significant (Figure 6D). At 
higher magnifications (20× or 40×) MBP-positive stained myelin 
 recovery time (F
2, 89
 = 6.73; p = 0.002), but no effect of treatment 
(F
4, 89
 = 1.69; p = NS). Post hoc comparisons showed no significant 
differences between any two antipsychotic groups (Figure 3A). In 
the second experiment, all animal groups except for HAL showed 
comparable SI time (Figure 3B). One-way ANOVA indicated a 
significant effect of the antipsychotics (F
4, 37
 = 8.88; p < 0.0001) on 
SI time of normal mice. Post hoc comparisons showed significant 
differences between the HAL group and the VEH, CLZ, and OLZ 
groups (p < 0.05).
atypIcal antIpsychotIc drugs, But not haloperIdol, proMoted 
the recovery of spontaneous alternatIon after cpZ 
wIthdrawal
All CPZ-withdrawn mice showed some improvement in spon-
taneous alternation during the 3-week recovery phase. Two-way 
ANOVA analysis indicated significant effects of both recovery 
time (F
2, 149
 = 30.4; p < 0.0001) and antipsychotic treatment 
(F
4, 149
 = 6.97, p < 0.0001), with an interaction that was almost 
significant (F
8, 149
 = 1.97; p = 0.055). For CLZ, OLZ, and QUE 
groups, spontaneous alternation measured on day 14 was sig-
nificantly higher than those measured on day 0. For HAL and 
VEH groups, significant increases in spontaneous alternation 
were recorded on day 21, although their values were still lower 
compared to CNT (see the dotted line in Figure 4A). For effects 
of antipsychotic drugs on the spontaneous alternation of normal 
mice, one-way ANOVA showed a significant effect of the antipsy-
chotics (F
4, 49
 = 2.58, p = 0.05; Figure 4B). Post hoc comparisons 
found a significant difference between HAL and CLZ groups 
(57 ± 4 over 70 ± 4, p = 0.03), but no group was significantly 
different from VEH group.
Figure 6 | incomplete recovery of myelin breakdown in the neocortex 
(CTX) after CPZ withdrawal. (A) An image from a mouse of the control (CNT) 
group showing normal MBP-labeled neural fibers which traverse the CTX from 
deep to superficial layers in parallels. (B) An image from a mouse of the CPZ 
group showing widespread myelin breakdown in CTX. (C) An image from a 
mouse treated with VEH during the 3-week recovery period after CPZ 
withdrawal. (D) The quantitative data (mean ± SEM; n = 5/group). The dotted line 
indicates the value of the CNT group, which was significantly higher than the 
CPZ group. **p < 0.01, compared to the CPZ group. The scale bar in the image 
(C) represents about 300 μm.
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mice with the status of white matter anomalies during a recovery 
period, since remyelination happens automatically following CPZ 
withdrawal (Matsushima and Morell, 2001; Skripuletz et al., 2008; 
Makinodan et al., 2009; Werner et al., 2010).
Behavioral recovery in EPM was complete at the end of second 
week after CPZ withdrawal in VEH group (Figure 2A). This rapid 
and complete recovery did not parallel the remyelination process, 
which was not yet finished on day 21 (Figures 5–7). These results 
suggest that the white matter damage seen in CPZ-treated mice was 
not a main contributor to this abnormal behavior. In support of this 
suggestion, in a recent study mice showed increased time on open 
arms of EPM beginning on day 14 following CPZ-feeding when no 
obvious demyelination was observed (Xu et al., 2009). We specu-
late that this abnormal behavior could be attributed to increased 
concentrations of inflammatory cytokines as mRNAs coding for 
many cytokines increase, with peak expression in fourth week fol-
lowing CPZ-feeding (Jurevics et al., 2002). Further supporting 
evidence to this speculation includes: the demyelinating effect of 
CPZ was shown to be initiated through secretion of tumor necrosis 
factor-α and interferon-γ (Cammer, 1999; Pasquiini et al., 2007); 
intracerebral injection of interleukin-1β resulted in acute white 
matter and neuronal injury in the neonatal rat (Cai et al., 2004; 
Fan et al., 2009); and mice with white matter damage, including 
loss of mature oligodendrocytes and impaired myelination induced 
by interleukin-1β exposure, spent longer periods on open arms of 
EPM (Fan et al., 2010).
sheaths of CPZ-withdrawn mice were short and seemed to be dis-
connected (not shown), suggesting the existence of incomplete 
myelin sheaths.
Mature oligodendrocytes labeled with GST-pi are distinctly 
detectable in brain sections (Figure 7). Exposure to CPZ for 
5 weeks almost completely depleted the GST-pi cells in CTX 
(Figure 7B). After 3 weeks recovery, GST-pi cells increased in the 
same brain region (Figure 7C). One-way ANOVA performed for 
the quantitative data in experiment 1 showed no significant effect 
(F
4, 24
 = 1.29; p = NS) of treatment on the number of GST-pi cells 
in CTX. Post hoc comparisons showed no differences between VEH 
and any antipsychotic group as well as between any two antipsy-
chotic groups. All CPZ-withdrawn mice had many more GST-pi 
cells compared to the CPZ-fed mice, but the numbers were still 
much lower than that of the CNT group (see the dotted line in 
Figure 7D).
dIscussIon
The abnormal behaviors and obvious demyelination, myelin break-
down, and oligodendrocyte loss seen in C57BL/6 mice given CPZ-
containing diet for 5 weeks confirmed the results reported in recent 
studies (Xiao et al., 2008; Koutsoudaki et al., 2009; Makinodan et al., 
2009; Norkute et al., 2009; Xu et al., 2009). Therefore, a correlation 
between white matter damage and certain behavioral abnormalities 
in the CPZ-treated mice is suggested. Moreover, this animal model 
allowed us to correlate the behavioral dynamics in CPZ-withdrawn 
Figure 7 | incomplete recovery of the loss of mature OLs in CTX after CPZ 
withdrawal. (A) An image showing GST-pi positive cells in CTX of a mouse of 
the control (CNT) group. (B) An image from a mouse of the CPZ group in which 
only a few GST-pi positive cells left in CTX after CPZ treatment. (C) An image 
showing GST-pi positive cells in CTX of a mouse treated with VEH during the 
3-week recovery period after CPZ withdrawal. (D) The quantitative data 
(mean ± SEM; n = 5/group). The dotted line indicates the value of the CNT 
group, which was significantly higher than all other groups. **p < 0.01, 
compared to the CPZ group. The scale bar in image (C) represents 
about 25 μm.
Frontiers in Behavioral Neuroscience www.frontiersin.org July 2011 | Volume 5 | Article 31 | 7
Xu et al. Effects of antipsychotics in cuprizone-exposed mice
adverse effects on white matter in humans. Nevertheless, the 
detrimental effect of HAL on SI may help explain why conven-
tional antipsychotics have only a modest or no effect on negative 
symptoms of patients with schizophrenia, as illustrated in a recent 
human study in which HAL was inferior to aripiprazole, an atypi-
cal antipsychotic drug, in improving PANSS items related to social 
functioning (Docherty et al., 2010).
Spontaneous alternation showed significant, but not complete, 
recovery in VEH group after CPZ withdrawal (Figure 4A). This 
paralleled the remyelination process seen in CPZ-withdrawn mice, 
suggesting a causal relationship between white matter damage and 
this behavioral abnormality. However, it should be noted that, in 
an earlier study, decreased spontaneous alternation was also seen 
at the end of second week after CPZ-feeding when no obvious 
demyelination was found (Xu et al., 2009). Therefore, compro-
mised white matter is just one of contributors to the decreased 
spontaneous alternation in CPZ-treated mice. Among the other 
contributors are likely dysfunctional neurotransmitter systems, 
especially the DA and 5-HT systems. Supporting evidence for 
dysfunctional DA system in CPZ-treated mice includes findings of 
increased DA in the frontal cortex of CPZ-treated mice (Xu et al., 
2009) and that co-administration of HAL and CPZ prevented 
mice from spontaneous alternation decreases (Xu et al., 2010). 
Although the 5-HT system has not been examined in brains of 
CPZ-treated mice, the beneficial effect of all antipsychotic drugs 
on the recovery process of CPZ-induced spontaneous alterna-
tion impairments provide indirect supporting evidence for the 
presence of a dysfunctional 5-HT system following white mat-
ter damage. In accordance with this explanation, ketanserin (a 
5-HT2 receptor antagonist) and risperidone (which has affinities 
for both 5-HT2 and D2 receptors) significantly ameliorated a 
seizure-induced impairment of spontaneous alternation behav-
ior in rats (Hidaka et al., 2010). HAL, however, did not promote 
functional recovery (Figure 4A). This inefficacy is not surprising 
since that HAL has adverse effects on myelin and oligodendro-
cytes, as discussed earlier, and that it only binds to D2 receptors. 
Therefore, the CPZ-exposed mouse may be used as a new animal 
model to explore the neurobiological mechanisms of impaired 
spatial working memory in schizophrenia (Gold and Harvey, 
1993; Xu et al., 2011).
In summary, the abnormal performance of mice in EPM 
spontaneously recovered to normal levels within 2 weeks after 
CPZ withdrawal, suggesting that white matter abnormality is 
not a main contributor to this abnormal anxiety behavior in 
CPZ-treated mice. Reduced SI remained at low levels in all CPZ-
withdrawn mice during the 3-weeks recovery period, suggesting 
a resistance of the CPZ-induced SI deficit to the antipsychotic 
drugs tested in this study. Impaired spontaneous alternation 
in CPZ-treated mice significantly recovered after CPZ with-
drawal. CLZ, OLZ, and QUE, but not HAL, significantly pro-
moted this recovery process. The CPZ-induced white matter 
damage in mice did not completely recover within 3 weeks after 
CPZ withdrawal and none of the antipsychotic drugs tested 
seemed to accelerate the remyelination process. Although the 
antipsychotic drugs tested in this study neither improved the 
performance of CPZ-withdrawn mice in SIs nor promoted the 
recovery of damaged white matter, these results may be due to 
Mice treated with antipsychotic drugs showed the same 
recovery course of this anxiety behavior as the VEH group. This 
phenomenon may be explained by either one of the following 
possibilities: (1) the treatment paradigms tested in this study 
had no effect on recovery; (2) the doses chosen for these drugs 
in this study were not optimal for these mice and measures; (3) 
their effects were masked by the rapid spontaneous recovery. 
The first possibility is in line with the result that all the drugs 
did not influence EPM behavior in mice that had never been 
exposed to CPZ (Figure 2B). The second possibility warrants 
further studies using different doses of these antipsychotic drugs 
or using different antipsychotic drugs. In support of the third 
possibility, the dramatic increases in microglia and astrocytes at 
demyelinated sites were almost completely prevented by QUE 
concurrently administered to CPZ-fed mice (Zhang et al., 2008), 
and the same treatment effectively prevented the CPZ-fed mice 
from increases in time spent on open arms of EPM (Xu et al., 
2010). Future studies should test different doses of the drugs and 
schedule earlier EPM tests before day 14 after CPZ withdrawal 
so that possible beneficial effects of the antipsychotic drugs on 
the recovery process in CPZ-withdrawn mice might be detected.
The decreased SI time observed in CPZ-fed mice remained at 
low levels during the 3-week recovery phase in the VEH group 
(Figure 3A). This lack of behavioral improvement did not cor-
respond with the significant recovery of damaged white matter 
(Figures 5–7). However, this may only reflect the need for nearly 
intact myelination for normal SI to occur because the remyelina-
tion was incomplete by 21st day after CPZ withdrawal (Figure 5) 
and the number of mature oligodendrocytes in CTX was still 
low at the same time (Figure 7). Further, work of others showed 
that SI deficits in CPZ-fed mice disappeared after a longer recov-
ery period (6 weeks) which allowed a complete remyelination 
(Makinodan et al., 2009). Finally, concurrent administration of 
CLZ or QUE with CPZ effectively protected mice against the 
CPZ-induced white matter damage (Zhang et al., 2008; Xu et al., 
2010) and SI deficits (Xu et al., 2010). Taken together, the data 
strongly suggest that intact brain myelin is essential for mice to 
perform normal SI.
None of the antipsychotic drugs tested in this study promoted 
the recovery of either SI decrease (Figure 3A) and or white matter 
remyelination (Figure 5) in CPZ-withdrawn mice. These results 
are in contrast to the effective prophylactic effects of CLZ/QUE as 
shown in our recent studies (Zhang et al., 2008; Xu et al., 2010). 
Extrapolation of these findings suggests that (atypical) antipsy-
chotic drugs should be given to schizophrenia patients as soon as 
possible to achieve better outcomes.
In normal mice that had never been exposed to CPZ, HAL, but 
not atypical antipsychotic drugs (CLZ, OLZ, and QUE), reduced 
SI time (Figure 3B). These results are similar to previous reports 
that HAL decreased social behavior of marmosets (Scraggs et al., 
1979) and of rats (Corbett et al., 1993). Since intact myelin sheath in 
the brain is essential to normal SI as discussed above, it is plausible 
to speculate that chronic administration of HAL might, by itself, 
have adverse effects on white matter. In support of this specula-
tion, it has been shown that chronic HAL treatment decreased the 
 expression of myelin/oligodendrocyte-related genes in the mouse 
brain (Narayan et al., 2007). It is unknown if HAL has similar 
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